NO971683L - Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende - Google Patents

Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende

Info

Publication number
NO971683L
NO971683L NO971683A NO971683A NO971683L NO 971683 L NO971683 L NO 971683L NO 971683 A NO971683 A NO 971683A NO 971683 A NO971683 A NO 971683A NO 971683 L NO971683 L NO 971683L
Authority
NO
Norway
Prior art keywords
reversible
freeze
pharmaceutical preparation
gelatinization
thermogelatin
Prior art date
Application number
NO971683A
Other languages
English (en)
Other versions
NO971683D0 (no
Inventor
Masanobu Takeuchi
Hiroe Suzuki
Toshie Takahashi
Hiroki Muruyama
Miyako Sasaki
Keiko Naito
Touro Oguma
Makoto Maeda
Original Assignee
Wakamoto Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakamoto Pharma Co Ltd filed Critical Wakamoto Pharma Co Ltd
Publication of NO971683D0 publication Critical patent/NO971683D0/no
Publication of NO971683L publication Critical patent/NO971683L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Frysetørket farmasøytisk preparat fremstilt ved å frysetørke en vandig bland- ing som har egenskapen reversibel varm- herdende gelatinering, oinfattende en effektiv mengde av et medikament, 0,2-2,1 vekt/vol% metylcellulose (metoksylgruppe-innhold i området 26-33%), 1,2-2,3 vekt/vol% sitronsyre og 0,5-13 vekt/vol% polyetylenglykol (PEG). Det frysetørkede farmasøytiske preparat muliggjør stabil lagring av medikamenter som er ustabile overfor vann, inntil de kan tas i praktisk bruk. Ved terapeutisk anvendelse kan preparat- et umiddelbart rekonstitueres ved til- f^r:i-f-r^ i !^^^1 *^..- stituering slik at det oppnås en vandig blanding som har egenskapen reversibel, varmherdende gelatinering, og den undergår gelatinering ved påføring lokalt.
NO971683A 1994-10-13 1997-04-11 Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende NO971683L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1994/001709 WO1996011672A1 (en) 1994-10-13 1994-10-13 Lyophilized preparation providing reversibly thermogelling water-base medicinal composition

Publications (2)

Publication Number Publication Date
NO971683D0 NO971683D0 (no) 1997-04-11
NO971683L true NO971683L (no) 1997-06-12

Family

ID=14098719

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971683A NO971683L (no) 1994-10-13 1997-04-11 Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende

Country Status (6)

Country Link
US (1) US5756552A (no)
EP (1) EP0782850A4 (no)
KR (1) KR100215739B1 (no)
FI (1) FI971533L (no)
NO (1) NO971683L (no)
WO (1) WO1996011672A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
WO1999045869A1 (en) * 1998-03-09 1999-09-16 Ista Pharmaceuticals, Inc. Use of corneal hardening agents in enzyme orthokeratology
US6458341B1 (en) * 1998-06-04 2002-10-01 3M Innovative Properties Company Devices with coatings containing chlorhexidine gluconate, compositions and methods
ES2155027B1 (es) * 1999-05-24 2001-12-01 Univ Pais Vasco Geles para propositos multiples, reversibles y degradables.
WO2001047542A1 (en) * 1999-12-28 2001-07-05 Meiji Seika Kaisha, Ltd. Vancomycin preparations
US6413537B1 (en) * 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
EP1328214A4 (en) * 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
US20050080043A1 (en) * 2000-09-20 2005-04-14 Lee Shahinian Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
SE0401321D0 (sv) * 2004-05-25 2004-05-25 John Aakerlund Elektronisk stickpropp och adapterkabel, samt generellt elektroniskt brytelement i väggströmställare och elektroniska säkringar med överströmskydd för allström mm
US7658947B2 (en) 2004-06-25 2010-02-09 Kimberly-Clark Worldwide, Inc. Thermo-gelling composition
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US8709310B2 (en) 2011-01-05 2014-04-29 Hospira, Inc. Spray drying vancomycin
DK2883104T3 (da) 2012-08-10 2024-07-29 Osio Corp D/B/A Yolia Health Anvendelse af kontaktlinse ved behandling af en ofthalmologisk lidelse
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
ES2648367T3 (es) 2013-10-22 2018-01-02 Medac Gesellschaft für klinische Spezialpräparate mbH Procedimiento de preparación de una composición farmacéutica liofilizada que contiene mitomicina C
WO2020025069A1 (zh) 2018-08-03 2020-02-06 上海宣泰医药科技有限公司 一种水化环磷酰胺冻干组合物的方法及其产品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6509059A (no) * 1964-07-22 1966-01-24
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
GB8426922D0 (en) * 1984-10-24 1984-11-28 Sandoz Ltd Galenic formulation
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
AU626840B2 (en) * 1988-02-26 1992-08-13 Genentech Inc. Human relaxin formulation
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
RU2108112C1 (ru) * 1993-04-16 1998-04-10 Вакамото Фармасьютикал Ко., Лтд. Водная лекарственная композиция, обладающая свойством обратимого терморегулируемого гелеобразования

Also Published As

Publication number Publication date
FI971533A7 (fi) 1997-04-11
FI971533A0 (fi) 1997-04-11
NO971683D0 (no) 1997-04-11
AU684558B2 (en) 1997-12-18
EP0782850A4 (en) 1998-03-04
US5756552A (en) 1998-05-26
WO1996011672A1 (en) 1996-04-25
FI971533L (fi) 1997-04-11
AU7862994A (en) 1996-05-06
KR100215739B1 (ko) 1999-08-16
EP0782850A1 (en) 1997-07-09
KR970705978A (ko) 1997-11-03

Similar Documents

Publication Publication Date Title
NO971683L (no) Lyofilisert farmasöytisk preparat som gjör vandige medikamentblandinger reversibelt termogelatinerende
US5082863A (en) Pharmaceutical composition of florfenicol
YU46012B (sh) Postupak za izradu vodenih gelirajućih rastvora derivata arilpropionske kiseline koji mogu da se resporbuju kroz kožu
NO973730L (no) Faste virkestofftilberedninger
NO974618L (no) Farmasöytiske preparater for intranasal administrasjon
NO965012D0 (no) Farmasöytisk preparat som omfatter glukagon
NO893239D0 (no) Farmasoeytisk preparat for behandling av diabetes mellitus.
CA2282513A1 (en) Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
CN1195524A (zh) 药物制剂
KR910019618A (ko) 발기부전증 치료용 제약 조성물
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
DE69531736D1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
GEP20053581B (en) Pharmaceutical Composition and Method for Preparation Thereof
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
CA2202520A1 (en) Lyophilized pharmaceutical preparations capable of providing aqueous drug composition having property of reversible thermosetting gelation
KR900015732A (ko) 경구용 제제
EP0492747A3 (en) Pharmaceutical preparation for topical application
ATE220325T1 (de) Pharmazeutische verwendungen von zypressen
RU2000112924A (ru) Применение глюкозаминоглюканов для получения фармацевтических препаратов для лечения связанных с диабетом глазных болезней
KR960010013A (ko) 진통약물과 생강추출처리물로 이루어진 진통효과 상승작용 조성물